Enzyme replacement therapy (ERT) with agalsidase alfa may slow deterioration of kidney function in men with Fabry disease, provided the treatment is started early, suggests a new study.
Enzyme replacement therapy (ERT) with agalsidase alfa may slow deterioration of kidney function in men with Fabry disease, provided the treatment is started early, suggests a new study.
Without treatment, Fabry disease causes progressive loss of kidney function, eventually leading to end-stage renal disease.
World Kidney Day
A report on World Kidney Day, 2008. The focus of this health day is on early detection of chronic kidney disease.
A report on World Kidney Day, 2008. The focus of this health day is on early detection of chronic kidney disease.
"The results provide further evidence that ERT with agalsidase alfa may slow the progression of kidney disease, provided that ERT is initiated early in the disease process," said Michael L. West, MD (Dalhousie University, Canada).
For the study, researchers pooled the results of three previous clinical trials of ERT with agalsidase alfa in 108 men with Fabry disease-a rare genetic disorder.
During treatment with an inactive placebo, kidney function declined rapidly.
By comparison, during treatment with agalsidase alfa (1 to 4.5 years), the rate of decline slowed considerably.
Advertisement
Rare Genetic Disorder Could Cause Strokes In Young People
A rare genetic disorder may be responsible for causing strokes in young people, though the condition's progress can be slowed using enzyme replacement treatment, says a study
A rare genetic disorder may be responsible for causing strokes in young people, though the condition's progress can be slowed using enzyme replacement treatment, says a study
"This underlines the importance of prompt diagnosis and intervention in patients with Fabry disease," West said.
Advertisement
Source-ANI
GPL
